Although body mass index (BMI) has been associated with inferior outcomes in gastrointestinal malignancies, it appears to have no bearing on surgical complications or survival in patients with esophageal adenocarcinoma who underwent esophagectomy after neoadjuvant chemoradiotherapy (nCRT).
An analysis of 303 such patients uncovered no difference in overall survival or disease-free survival associated with BMI. Kenneth L. Meredith, MD, of the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and fellow investigators also reported in Journal of Gastrointestinal Surgery that they found no differences in postoperative complications or mortality among the patients, who had been classified into four groups based on BMI:
- ≤25
- 25-30
- >30-35
- >35
Multivariate analysis revealed that none of the following factors were prognostic for worse overall or disease-free survival: BMI, age, gender, type of surgery, or year of diagnosis. However, a higher tumor stage and a less than complete response to nCRT were prognostic for worse overall and disease-free survival.
Continue Reading
